Figure 2.

In vivo antiviral drug dosage assessment: ABE-mediated concentration-dependent reduction of spleen-specific MCMV viral load. Oral application of ABE in dosages of (A) 20 mg/kg/d over 4 days and (B) 50 mg/kg/d or 100 mg/kg/d over 5 days, resulting in a reduction in viral load of 44%, 74% or 87%, respectively, compared to vehicle-treated animals. Data are presented as mean + SD of viral replication across five animals per group as measured using in vitro luciferase assay performed on spleen homogenates.